Morphological changes induced by Intraprostatic PSA-based vaccine in prostate Cancer biopsies (phase I clinical trial)
This study evaluated the histopathological effects in prostate biopsies of recombinant fowlpox (rF) virus-based vaccine engineered to present the PSA and three costimulatory molecules (collectively labeled as PSA-TRICOM). This vaccine has shown that it can break tolerance of the PSA, and its administration directly into a tumor enables the affected tumor cells to act as antigen-presenting cells activating new T-cells, and broadening the immune response to recognize and kill tumor.
Source: Human Pathology - Category: Pathology Authors: Maria J Merino, A Peter, Vanessa Moreno, Sara Gil, Jeffrey Schlom, James L Gulley Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Immunotherapy | Pathology | Prostate Cancer | Study | Vaccines